Arcellx, Inc. (ACLX)
$89.07
Market is closed - opens 8 PM, 29 Nov 2024
Performance
- $88.56$92.93$89.07
0.57%
Downside
Day's Volatility :4.7%
Upside
4.15%
- $46.42$107.37$89.07
47.88%
Downside
52 Weeks Volatility :56.77%
Upside
17.04%
Returns
| Period | Arcellx, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 27.27% | -6.1% | 0.0% |
6 Months | 77.31% | 1.2% | 0.0% |
1 Year | 70.95% | 12.2% | 0.0% |
3 Years | 441.43% | 10.8% | -21.2% |
Highlights
Market Capitalization | 4.9B |
Book Value | $8.95 |
Earnings Per Share (EPS) | -0.71 |
Wall Street Target Price | 111.813 |
Profit Margin | -25.94% |
Operating Margin TTM | -129.14% |
Return On Assets TTM | -6.29% |
Return On Equity TTM | -10.79% |
Revenue TTM | 155.8M |
Revenue Per Share TTM | 2.98 |
Quarterly Revenue Growth YOY | 74.0% |
Gross Profit TTM | 0.0 |
EBITDA | -65.3M |
Diluted Eps TTM | -0.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.5 |
EPS Estimate Next Year | -2.23 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.6 |
Analyst Recommendation
Buy
95%Buy
4%Hold
0
0%Sell
Based on 21 Wall street analysts offering stock ratings for Arcellx, Inc.(by analysts ranked 0 to 5 stars)
Based on 21 analyst
- Current
- 1M Ago
- 3M Ago
Buy
20
20
19
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 25.53%
Current $89.07
Target $111.81
Technicals Summary
Sell
Neutral
Buy
Arcellx, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Arcellx, Inc. | 7.02% | 77.31% | 70.95% | 441.43% | 441.43% |
 Regeneron Pharmaceuticals, Inc. | -18.91% | -22.62% | -5.64% | 15.07% | 102.66% |
 Biontech Se | 4.66% | 25.97% | 22.38% | -67.3% | 441.77% |
 Alnylam Pharmaceuticals, Inc. | -11.7% | 68.83% | 59.14% | 40.17% | 115.51% |
 Vertex Pharmaceuticals Incorporated | -1.95% | 4.52% | 33.38% | 145.68% | 112.25% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Arcellx, Inc. | NA | NA | NA | -1.5 | -0.11 | -0.06 | NA | 8.95 |
Regeneron Pharmaceuticals, Inc. | 18.25 | 18.25 | 1.1 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Arcellx, Inc. | Buy | $4.9B | 441.43% | NA | -25.94% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.1B | 102.66% | 18.25 | 33.61% |
Biontech Se | Buy | $27.1B | 441.77% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 115.51% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $118.9B | 112.25% | 32.84 | -4.51% |
Institutional Holdings
FMR Inc
12.00%Paradigm Biocapital Advisors LP
7.41%Perceptive Advisors LLC
7.20%NEA Management Company, LLC
6.94%BlackRock Inc
6.51%Vanguard Group Inc
4.56%
Corporate Announcements
Arcellx, Inc. Earnings
Arcellx, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
Organization | Arcellx, Inc. |
Employees | 130 |
CEO | Mr. Rami Elghandour |
Industry | Healthcare |
